Skip to main content
Premium Trial:

Request an Annual Quote

Atugen and Asinex Pen Drug Discovery Alliance

NEW YORK, Feb. 7 (GenomeWeb News) - Atugen and Asinex have signed a cancer drug discovery and development collaboration, the companies said today.


The two partners aim to develop compounds directed against PKN3, a kinase target involved in prostate cancer. Atugen, based in Berlin, focuses on siRNA-based drugs and will contribute its target discovery and in vivo screening expertise. Asinex, located in Moscow, will provide its drug design, medicinal chemistry, and in vitro screening knowledge.


The companies said they will share the risk of the research and split future revenues equally.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.